Binding to the low-density lipoprotein receptor accelerates futile catalytic cycling in PCSK9 and raises the equilibrium level of intramolecular acylenzyme

Biochemistry

Volumn 48, Issue 13, 2009, Pages 2941-2949

  Geoghegan, Kieran F ^a   Hoth, Lise R ^a   Varghese, Alison H ^a   Lin, Wen ^a   Boyd, James G ^a   Griffor, Matthew C ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITES; CATALYTIC ACTIVITIES; CATALYTIC CYCLING; CATALYTIC DOMAINS; CONFORMATIONAL STATE; EXTRACELLULAR DOMAINS; FINAL STATE; LOW-DENSITY LIPOPROTEINS; OXYGEN ISOTOPES; PEPTIDE MAPPINGS; PEPTIDE SYNTHESIS; PROPEPTIDE; PROTEOLYTIC ACTIVITIES; SUBTILISIN; TARGET CELLS; TIME POINTS; WILD TYPES;

AMINES; CARBOXYLATION; INTERNET; MASS SPECTROMETRY; OXYGEN;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CARBOXYLIC ACID; GLUTAMINE; ISOTOPE; KEXIN; LOW DENSITY LIPOPROTEIN RECEPTOR; OXYGEN 18; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SOLVENT; UNCLASSIFIED DRUG; WATER;

AMINO TERMINAL SEQUENCE; ARTICLE; ATOM; CATALYSIS; COMPLEX FORMATION; DIGESTION; EQUILIBRIUM CONSTANT; EXPERIMENT; HUMAN; HYDROLYSIS; MASS SPECTROMETRY; MUTANT; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; RECEPTOR BINDING; WILD TYPE;

ANIMALS; BIOCATALYSIS; CHO CELLS; CRICETINAE; CRICETULUS; GLUTAMINE; HUMANS; ISOTOPES; MASS SPECTROMETRY; MUTANT PROTEINS; PEPTIDES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; SUBSTRATE CYCLING;

EID: 65249085584     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi802232m     Document Type: Article

References (33)

1. Seidah, N. G., Mayer, G., Zaid, A., Rousselet, E., Nassoury, N., Poirier, S., Essalmani, R., and Prat, A. (2008) The activation and physiological functions of the proprotein convertases. Int. J. Biochem. Cell Biol. 40, 1111-1125.
2. Henrich, S., Lindberg, I., Bode, W., and Than, M. E. (2005) Proprotein convertase models based on the crystal structures of furin and kexin: Explanation of their specificity. J. Mol. Biol. 345, 211-227.
3. Attie, A. D. (2004) The mystery of PCSK9. Arterioscler., Thromb., Vasc. Biol. 24, 1337-1339.
4. Lopez, D. (2008) PCSK9: An enigmatic protease. Biochim. Biophys. Acta 1781, 184-191.
5. Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2007) Molecular biology of PCSK9: Its role in LDL metabolism. Trends Biochem. Sci. 32, 71-77.
6. Seidah, N. G., Khatib, A. M., and Prat, A. (2006) The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol. Chem. 387, 871-877.
7. Cameron, J., Holla, O. L., Ranheim, T., Kulseth, M. A., Berge, K. E., and Leren, T. P. (2006) Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 15, 1551-1558.
8. Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., Mansour, M. N., McGrath, K. M., Seddon, A. P., Shenolikar, S., Stutzman-Engwall, K. J., Warren, L. C., Xia, D., and Qiu, X. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14, 413-419.
9. Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., and Horton, J. D. (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116, 2995-3005.
10. Qian, Y.-W., Schmidt, R. J., Zhang, Y., Chu, S., Lin, A., Wang, H, Wang, X., Beyer, T. P., Bensch, W. R., Li, W., Ehsani, M. E., Lu, D., Konrad, R. J., Eacho, P. I., Moller, D. E., Karathanasis, S. K., and Cao, G. (2007) Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J. Lipid Res. 48, 1488-1498.
11. Schmidt, R. J., Beyer, T. P., Bensch, W. R., Qian, Y.-W., Lin, A., Kowala, M., Alborn, W. E., Konrad, R. J., and Cao, G (2008) Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem. Biophys. Res. Commun. 370, 634-640.
12. Costet, P., Krempf, M., and Cariou, B. (2008) PCSK9 and LDL cholesterol: Unravelling the target to design the bullet. Trends Biochem. Sci. 33, 426-434.
13. Abifadel, M., Varret, M., Rabes, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derre, A., Villeger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C, Seidah, N. G., and Boileau, C. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156.
14. Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr., and Hobbs, H. H. (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272.
15. Maxwell, K N., Fisher, E. A., and Breslow, J. L. (2005) Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. U.S.A. 102, 2069-2074.
16. Tall, A. R. (2006) Protease variants, LDL, and coronary heart disease. N. Engl. J. Med. 354, 1310-1312.
17. Li, J., Tumanut, C., Gavigan, J.-A., Huang, W.-J., Hampton, E. N, Tumanut, R., Suen, K. F., Trauger, J. W., Spraggon, G., Lesley, S. A., Liau, G., Yowe, D., and Harris, J. L. (2007) Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem. J. 406, 203-207.
18. McNutt, M. C., Lagace, T. A., and Horton, J. D. (2007) Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J. Biol. Chem. 282, 20799-20803.
19. Nassoury, N., Blasiole, D. A., Oler, A. T., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., and Seidah, N. G. (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8, 718-732.
20. Piper, D. E., Jackson, S., Liu, Q., Romanow, W. G., Shetterly, S., Thibault, S. T, Shan, B., and Walker, N. P. C. (2007) The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol. Structure (Cambridge, MA, U.S.) 15, 545-552.
21. Hampton, E. N., Knuth, M. W., Li, J., Harris, J. L., Lesley, S. A., and Spraggon, G. (2007) The self-inhibited structure of full-length PCSK9 at 1.9 angstrom reveals structural homology with resistin within the C-terminal domain. Proc. Natl. Acad. Sci. U.S.A. 104, 14604-14609.
22. Tanaka, S., Matsumura, H., Koga, Y., Takano, K., and Kanaya, S. (2007) Four new crystal structures of Tk-subtilisin in unautoprocessed, autoprocessed and mature forms: Insight into structural changes during maturation. J. Mol. Biol. 372, 1055-1069.
23. Jain, S. C., Shinde, U., Li, Y., Inouye, M., and Berman, H. M. (1998) The crystal structure of an autoprocessed Ser221Cys-subtilisin E-propeptide complex at 2.0 angstrom resolution. J. Mol. Biol. 284, 137-144.
24. Naoumova, R. P., Tosi, I., Patel, D., Neuwirth, C., Horswell, S. D., Marais, A. D., van Heyningen, C., and Soutar, A. K. (2005) Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene. Arterioscler., Thromb., Vasc. Biol. 25, 2654-2660.
25. Zhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282, 18602-18612.
26. Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D., and Deisenhofer, J. (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. U.S.A. 105, 1820-1825.
27. Anderson, E. D., VanSlyke, J. K., Thulin, C. D., Jean, F., and Thomas, G. (1997) Activation of the furin endoprotease is a multiple-step process: Requirements for acidification and internal propeptide cleavage. EMBO J. 16, 1508-1518.
28. Anderson, E. D., Molloy, S. S., Jean, F., Fei, H., Shimamura, S., and Thomas, G. (2002) The ordered and compartment-specific autoproteolytic removal of the furin intramolecular chaperone is required for enzyme activation. J. Biol. Chem. 277, 12879-12890.
29. Nour, N., Basak, A., Chretien, M., and Seidah, N. G. (2003) Structure-function analysis of the prosegment of the proprotein convertase PC5A. J. Biol. Chem. 278, 2886-2895.
30. Rudenko, G., Henry, L., Henderson, K., Ichtchenko, K., Brown, M. S., Goldstein, J. L., and Deisenhofer, J. (2002) Structure of the LDL receptor extracellular domain at endosomal pH. Science 298, 2353-2358.
31. Shan, L., Pang, L., Zhang, R., Murgolo, N. J., Lan, H., and Hedrick, J. A. (2008) PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem. Biophys. Res. Commun. 375, 69-73.
32. Bottomley, M. J., Cirillo, A., Orsatti, L., Ruggeri, L., Fisher, T. S., Santoro, J. C., Cummings, R. T., Cubbon, R. M., Lo Surdo, P., Calzetta, A., Noto, A., Baysarowich, J., Mattu, M., Talamo, F., De Francesco, R., Sparrow, C. P., Sitlani, A., and Carfi, A. (2009) Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J. Biol. Chem. 284, 1313-1323.
33. Zhang, D.-W., Garuti, R., Tang, W.-J., Cohen, J. C., and Hobbs, H. H. (2008) Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. U.S.A. 105, 13045-13050.